Home / Science / The industry today
Veriphase · Explained simply
Not a list of vendors. A description of the layers a peptide passes through before it reaches you, and which of them is obliged to check anything.
Ask most buyers who made the peptide they are holding and the honest answer is that they do not know. Often the person who sold it does not know either.
That is not usually deception. It is the shape of the industry. A peptide typically passes through four or five separate businesses on its way to a Canadian vial, and each one knows its immediate neighbours and very little else.
What this page is and is notThis describes how the supply chain is structured. It names no companies, recommends no suppliers, and offers no guidance on purchasing. We test samples; we do not source them, and we have no interest in helping anyone source them.
It exists because understanding the chain explains why testing exists at all — and because a customer who knows how the industry works reads a certificate more carefully.
Almost all synthetic peptide in circulation originates from a relatively small number of countries, with China dominant and India, South Korea and parts of the EU accounting for most of the rest. There are well over a thousand active pharmaceutical ingredient manufacturers in China alone; several hundred are registered with foreign regulators.
The important thing to understand is that this is not a separate underworld. Some of the same facilities that supply regulated pharmaceutical companies also sell bulk peptide into unregulated channels. The difference between those two output streams is not necessarily the chemistry — it is which quality system, documentation and oversight the batch was produced under.
A minority operate under Good Manufacturing Practice standards with the certifications and audit trails that implies. Most do not, and are not required to.
This is the layer where the synthesis quality is determined — stepwise efficiency, purification, how carefully the crude mixture was separated. It is also the layer furthest from the buyer and the one they will never see.
Bulk peptide arrives as a quantity of powder. Somebody has to weigh it into individual vials, freeze-dry it, seal it, apply a label and put a number on that label.
This is a distinct business from making the molecule, and it is frequently done by a different company in a different place. It is also where a large share of quality variation enters, because the accuracy of the amount in your vial is decided here rather than at the factory.
That is worth reading twice. The largest available analysis of gray-market peptides found that the most common failure was not the wrong compound or poor purity — it was the wrong amount in the vial. Roughly a third of samples were the right peptide at an acceptable purity in a quantity that missed the label.
The molecule and the milligrams are decided by different companies, in different buildings, often in different countries.
Product reaching Canada arrives either in bulk to a domestic distributor, or directly to individual buyers by international post. Both routes exist and behave very differently.
Bulk import concentrates the customs risk on one party and lets a distributor hold stock domestically. Direct-to-consumer international shipping distributes that risk across thousands of small parcels, which is one reason the model persists.
What neither route involves is a mandatory quality check on entry. Customs enforcement is concerned with what may lawfully cross a border, not with whether the contents match the label.
These are the websites. Some hold their own stock, some ship on behalf of an upstream supplier, and some are effectively storefronts over a shared inventory. From the outside these look identical, and a buyer generally cannot tell which they are dealing with.
Vendors are where the “research use only” framing lives — a designation intended to place the product outside the regulatory framework that governs medicines. It is a label describing a legal position, not a description of what has been verified about the contents.
Many vendors publish certificates of analysis. Those certificates were commissioned and paid for by the vendor, and typically cover a batch rather than the specific vial you receive.
A small number of analytical laboratories worldwide accept samples for identity, purity and content testing. Some accept submissions from individuals; others work only with businesses.
This layer exists because the four above it contain no mandatory verification. It is funded almost entirely by the people at the end of the chain, and it is entirely voluntary. Nobody is obliged to test anything, and nobody is penalised for not doing so.
We are part of this layer, which is a conflict of interest worth stating plainly. We think an independent measurement is worth having. We would think that regardless, but we also sell it.
Canadian regulation draws a line that does not match how the market is organised.
Some of these compounds are approved prescription drugs. Semaglutide has authorised products in Canada, and in 2026 Health Canada became the first G7 regulator to approve a generic version. Those products are manufactured under pharmaceutical quality systems, dispensed by pharmacists, and subject to recall if something goes wrong.
Others have no approved form anywhere. Retatrutide has not been authorised in any jurisdiction. BPC-157 has no approved pharmaceutical product. For these there is no regulated version to compare against and no official supply chain in existence.
The unregulated market spans both. The same vendor may list an approved-elsewhere compound alongside one that has never been through a regulatory process, under the same “research use only” heading, at similar prices, with similar-looking documentation.
“Research use only” is a statement about intended use, which places a product outside the rules governing medicines. It is not a quality standard, not a certification, and not a claim that anything has been verified.
We use the phrase ourselves, on every page, because it accurately describes what we sell. It says nothing, though, about what is in a vial.
Follow a vial back through those layers and something becomes clear: every layer adds a name, and none of them adds accountability.
The factory sold bulk powder to a customer who took delivery of it. The filler weighed out what they were given. The importer moved sealed goods. The vendor listed what they were sent. Each has fulfilled its obligation to the layer beside it, and no one anywhere has been required to establish that the final vial contains what the final label says.
That is not a claim that anyone in the chain is dishonest. Most are running ordinary businesses under the rules that apply to them. It is a claim about the structure: a supply chain with no mandatory verification produces unverified product, and it does so without anyone breaking a rule.
Domestic testing is becoming available. Until recently, a Canadian wanting an independent analysis shipped the sample to Europe and waited three to four weeks, with customs risk in both directions. That is no longer the only option.
Approved alternatives are appearing for some compounds. Generic semaglutide approval in Canada changes the calculus for that specific molecule, though it changes nothing for tirzepatide, retatrutide, or anything without an approved form.
Published research is starting to exist. Until 2026 there was almost no published data on what is actually in these products. There is now analysis covering thousands of samples, which is why this section can cite figures rather than impressions. The largest of those datasets is a preprint and has not been peer reviewed — a real limitation, and one worth carrying with every figure quoted from it.
You cannot audit a supply chain you cannot see, and nobody in it is obliged to audit it for you. What you can do is measure the one vial in front of you.
Verify always.
For research use only. Not for human or veterinary administration, and not a clinical or diagnostic service. This page describes the structure of a supply chain. It is not sourcing guidance, it does not name or recommend suppliers, and nothing here should be read as an endorsement of purchasing any product.